Microbiome-based therapeutics represent an emerging frontier in neurodegenerative disease treatment, targeting the bidirectional communication between the gastrointestinal tract and the central nervous system known as the gut-brain axis. This approach encompasses multiple strategies including fecal microbiota transplantation (FMT), probiotic therapies (psychobiotics), prebiotic interventions, postbiotic metabolites, and dietary modifications. The field has attracted significant investment as evidence mounts linking gut microbiome dysbiosis to Alzheimer's disease (AD), Parkinson's disease (PD), and ALS pathogenesis[1].
The global microbiome therapeutics market was valued at approximately $3.8 billion in 2024, with neurological applications representing the fastest-growing segment. Major pharmaceutical companies have established partnerships with specialized microbiome biotech firms to develop live biotherapeutic products (LBPs) for neurodegenerative indications[2].
Microbiome-based therapies exert neuroprotective effects through multiple established pathways[3]:
| Mechanism | Therapeutic Approach | Target Disease |
|---|---|---|
| Reduce systemic inflammation | FMT, probiotics | AD, PD, ALS |
| Restore blood-brain barrier integrity | Postbiotics, SCFAs | AD, PD |
| Modulate alpha-synuclein aggregation | Probiotics, prebiotics | PD |
| Decrease amyloid-beta burden | Dietary interventions, FMT | AD |
| Protect dopaminergic neurons | Psychobiotics | PD |
| Modulate TDP-43 pathology | Microbiome modulation | ALS |
| Drug/Program | Type | Company | Development Stage | Indication |
|---|---|---|---|---|
| Axial-101 | Psychobiotic | Axial Therapeutics | Phase II | PD, ASD |
| Axial-201 | Psychobiotic | Axial Therapeutics | Phase I | AD |
| CB-1801 (Finch-030) | LBP | Finch Therapeutics | Phase II | PD |
| CB-2101 (Finch-010) | LBP | Finch Therapeutics | Phase I | AD |
| VBL-01 | Vedanta LBP | Vedanta Biosciences | Phase I/II | PD |
| VE-202 | LBP | Vedanta Biosciences | Phase I | AD |
| SYNT-101 | Syntheticbiotic | Yumanity Therapeutics | Preclinical | PD |
| Yumanity-201 | LBP | Yumanity Therapeutics | Discovery | ALS |
| Microbiome Modulator A | Small molecule | Cerevel Therapeutics | Phase I | PD |
| CER-0001 (SBO) | LBP | Cerecin | Phase II | AD, PD |
Active and recent trials investigating microbiome-based approaches in AD[4]:
PD trials represent the most advanced microbiome therapeutic programs:
Emerging microbiome approaches in ALS:
Axial Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule psychobiotics that target the gut-brain axis. Their lead candidate, Axial-101, has shown promise in PD clinical trials, demonstrating improvements in motor symptoms and gastrointestinal function. The company raised $60 million in Series C funding in 2023[5].
Pipeline: Axial-101 (Phase II, PD), Axial-201 (Phase I, AD)
Vedanta Biosciences develops defined bacterial consortia as live biotherapeutic products (LBPs). Their platform generates rationally defined compositions of beneficial bacteria that can modulate immune function and inflammation. The company has partnerships with major pharmaceutical companies including Pfizer and Bristol Myers Squibb.
Pipeline: VBL-01 (Phase I/II, PD), VE-202 (Phase I, AD)
Finch Therapeutics specializes in microbial therapeutics derived from human data. Their platform uses machine learning to identify optimal bacterial compositions for specific diseases. The company went public in 2021 (NASDAQ: FNCH) and has since focused on neurological indications.
Pipeline: CB-1801 (Phase II, PD), CB-2101 (Phase I, AD)
Yumanity Therapeutics focuses on microbiome-based approaches for protein aggregation diseases, particularly PD and ALS. Their platform identifies bacterial metabolites that can inhibit toxic protein aggregation.
Pipeline: SYNT-101 (Preclinical, PD), Yumanity-201 (Discovery, ALS)
Cerecin (formerly known as Cerevast Therapeutics) develops microbiome-derived therapeutics for neurological disorders. Their lead compound CER-0001 is a defined bacterial strain being developed for AD and PD.
Pipeline: CER-0001 (Phase II, AD, PD)
The microbiome-neurodegeneration space has attracted significant investment[6]:
Key investment themes:
Despite progress, significant gaps remain in the microbiome-neurodegeneration field[7]:
| Gap Area | Current Status | Priority |
|---|---|---|
| Mechanistic understanding | Limited human data | High |
| Biomarker development | No validated biomarkers | High |
| Strain-specific effects | Unknown | Medium |
| Long-term safety data | Limited | Medium |
| Dose optimization | Not established | Medium |
This investment landscape page connects to the following NeuroWiki resources:
Cryan JF, O'Riordan KJ, Cowan CSM, et al. The Microbiota-Gut-Brain Axis. Physiological Reviews. 2019. ↩︎
Markets and Markets. Microbiome Therapeutics Market - Global Forecast to 2029. Markets and Markets Report. 2029. ↩︎
Needham BD, Kaddurah-Daouk R, Mazmanian SK. Gut microbial molecules in Behavioural and neurodegenerative conditions. Nature Reviews Neuroscience. 2020. ↩︎
ClinicalTrials.gov. Search: microbiome AND (Alzheimer's OR Parkinson's). ↩︎
Axial Therapeutics Press Release. Series C Funding Announcement. 2023. ↩︎
Dealroom, Crunchbase. Microbiome biotech investment data. 2024. ↩︎
Sampson TR, Mazmanian SK. Control of brain development, function, and behavior by the microbiome. Cell. 2015. ↩︎